News
FDA Clears nContact’s Cardiac Ablation Device, EPi-Sense with Embedded Sensors
MORRISVILLE, N.C.–(BUSINESS WIRE)–nContact, Inc. today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s modifications to its VisiTrax® cardiac ablation device, EPi-Sense®, now with embedded sensing capability. This next generation of technology includes sensors along the ablation device which provide real-time feedback to physicians conducting cardiac ablation procedures…
Read the full story here.